Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer

[1]  V. Bramwell,et al.  S35 CEF versus CMF in premenopausal women — Recent update , 1998 .

[2]  B Fisher,et al.  Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. , 1997, Journal of the National Cancer Institute.

[3]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[4]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[5]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Stephen E. Jones,et al.  Adjuvant Therapy of Cancer , 1990 .

[7]  G. Canellos.  The dose dilemma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Gelman,et al.  Dose-response in the treatment of breast cancer: a critical review. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. V. Von Hoff,et al.  Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Levine,et al.  Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  V. Devita.  Dose-response is alive and well. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Schnipper,et al.  Clinical implications of tumor-cell heterogeneity. , 1986, The New England journal of medicine.

[13]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Schabel,et al.  Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology , 1984, Pharmacology & therapeutics.

[15]  E. Gehan,et al.  Dose‐response and dose‐survival advantage for high versus low‐dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study , 1984, Cancer.

[16]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Redmond,et al.  The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. , 1983, Cancer treatment reports.

[18]  J. O'fallon,et al.  A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy , 1982, American journal of clinical oncology.

[19]  J. Holland,et al.  Adjuvant chemotherapy of breast cancer , 1979, Cancer.

[20]  B. Hoogstraten,et al.  Dose response evaluation of adriamycin in human neoplasia , 1977, Cancer.

[21]  R. Aur,et al.  Drug dosage and remission duration in childhood lymphocytic leukemia , 1971, Cancer.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[23]  M. Zelen,et al.  A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. , 1985, Cancer research.

[24]  Ludwig Breast.  Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Skoog,et al.  Tamoxifen and combination chemotherapy as adjuvant treatment in postmenopausal women with breast cancer. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[26]  H. Senn,et al.  Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer: 8 year results. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[27]  H. Mouridsen,et al.  Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[28]  R. K. Knight,et al.  A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[29]  G. Bonadonna,et al.  Dose-response effect of adjuvant chemotherapy in breast cancer. , 1981, The New England journal of medicine.

[30]  Hill Rp,et al.  Pulmonary metastases of the lewis lung tumor-cell kinetics and response to cyclophosphamide at different sizes. , 1977 .

[31]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .